6th Heidelberg Myeloma Workshop

Current status and developments in diagnosis and therapy of multiple myeloma

Congress venue:
Lecture hall, Klinik für Innere Medizin
Universitätsklinikum Heidelberg

Friday, May 5th 2017
Saturday, May 6th 2017

Prof. Dr. med. Hartmut Goldschmidt
Prof. Dr. med. Jens Hillengass
PD Dr. med. Marc-Steffen Raab
Prof. Dr. med. Carsten Müller-Tidow
Prof. Dr. med. Dirk Jäger
Prof. Dr. med. Christof von Kalle
Friday, 5\textsuperscript{th} of May

9:00 a.m. – 11:10 a.m.  
Congress Venue: NCT Heidelberg, Room K2/K3, Im Neuenheimer Feld 460

**PRE-CONFERENCE SCIENTIFIC WORKSHOP**  
on bone metabolism and bone substitute materials  
(related to the SFB Transregio 79)  
*Chairmen: Dirk Hose, Heidelberg/Christian Heiss, Gießen*

9:00 a.m. – 9:10 a.m.  
Opening remarks  
*Hartmut Goldschmidt, Heidelberg*

9:10 a.m. – 9:30 a.m.  
Pathophysiology of bone disease in multiple myeloma  
*Franz Jakob, Würzburg*

9:30 a.m. – 9:50 a.m.  
Interaction of bone disease and bone marrow microenvironment  
*Ulf Müller-Ladner, Gießen*

9:50 a.m. – 10:10 a.m.  
Prevention and treatment of malignant bone disease  
*Lorenz C. Hofbauer, Dresden*

10:10 a.m. – 10:30 a.m.  
Surgical treatment for benign and malignant bone defects  
*Christian Heiss, Gießen*

10:30 a.m. – 10:50 a.m.  
Development of bone substitute material for benign and malignant bone defects  
*Michael Gelinsky, Dresden*

10:50 a.m. – 11:10 a.m.  
Bortezomib releasing bone substitute materials targeting osteolytic bone disease in multiple myeloma  
*Dirk Hose, Heidelberg*

11:10 a.m. – 12:00 p.m. Coffee break, Snacks included
1:55 p.m. – 2:15 p.m.
**Genetic heterogeneity and genomic evolution in multiple myeloma**
Niels Weinhold, Little Rock

2:15 p.m. – 2:35 p.m.
**Clinical impact of epigenetics in multiple myeloma**
Gareth Morgan, Little Rock

2:35 p.m. – 3:00 p.m. Coffee break

3:00 p.m. – 5:00 p.m. **SESSION II**
**Diagnostics and Prognostic Factors**
Chairmen: Brian G.M. Durie, Los Angeles/Dirk Hose, Heidelberg

3:00 p.m. – 3:20 p.m.
**Role of modern imaging techniques in diagnosis and staging of patients with multiple myeloma**
Stefan Delorme, Heidelberg

3:20 p.m. – 3:40 p.m.
**Role of modern imaging techniques for prognosis and treatment monitoring**
Jens Hillengass, Heidelberg

3:40 p.m. – 4:00 p.m.
**Gene-expression profiling- and next generation sequencing in multiple myeloma**
Dirk Hose, Heidelberg

4:00 p.m. – 4:20 p.m.
**Mutational characterisation of multiple myeloma by investigation of circulating cell free DNA**
Andrew Spencer, Melbourne

4:20 p.m. – 4:40 p.m.
**Prognostic significance of sequencing-based MRD diagnostics**
Bruno Paiva, Pamplona

4:40 p.m. – 5:00 p.m.
**Integrating molecular risk markers for stratified medicine**
Martin Kaiser, London

5:00 p.m. – 5:20 p.m. Coffee break

5:20 p.m. – 6:20 p.m. **SESSION III**
**Role of Immunotherapy in Multiple Myeloma**
Chairmen: Gareth Morgan, Little Rock/Christof von Kalle, Heidelberg

5:20 p.m. – 5:40 p.m.
**Impact of immune checkpoint blockade**
Ashraf Badros, Baltimore

5:40 p.m. – 6:00 p.m.
**Targeting multiple myeloma with Car-T-cells-therapy**
Henk Lokhorst, Utrecht

6:00 p.m. – 6:20 p.m.
**Natural killer cell-based therapy**
Adelheid Cerwenka, Heidelberg

6:20 p.m. – 6:30 p.m. Summary day one
Hartmut Goldschmidt

7:30 p.m. Evening event
Saturday, 6th of May

8:30 a.m. – 10:00 a.m. KEY NOTE LECTURES

8:30 a.m. – 9:00 a.m.
Introducing Brian Durie (Hartmut Goldschmidt)
The “Black Swan” research initiative – First results on the way to a cure
Brian G.M. Durie, Los Angeles

9:00 a.m. – 9:30 a.m.
Introducing Ola Landgren (Jens Hillengass)
Potential cure by early detection and early treatment
Ola Landgren, New York

9:30 a.m. – 10:00 a.m.
Introducing Katja Weisel
Role of maintenance treatment in multiple myeloma
Michel Attal, Toulouse

10:00 a.m. – 10:30 a.m. Coffee break

10:30 a.m. – 11:50 a.m. SESSION IV
Therapy of Multiple Myeloma – Drugs and Treatment Strategies I
Chairmen: Henk Lokhorst, Utrecht/Christof Scheid, Köln

10:30 a.m. – 10:50 a.m.
Treatment decisions for patients ineligible for transplantation
Heinz Ludwig, Wien

10:50 a.m. – 11:10 a.m.
Optimization of therapy sequence
Michele Cavo, Bologna

11:10 a.m. – 11:30 a.m.
Long term survivors: What can we learn from them?
Saad Usmani, Charlotte

11:30 a.m. – 11:50 a.m.
Personalized therapy in relapsed multiple myeloma
Marc-Steffen Raab, Heidelberg

11:50 a.m. – 12:50 p.m. SESSION V
Treatment Paradigm of Multiple Myeloma
Chairmen: Hartmut Goldschmidt, Heidelberg/
Morie A. Gertz, Rochester

11:50 a.m. – 12:00 p.m.
Introduction: “Continuous therapy vs. fixed duration of therapy”
Morie A. Gertz, Rochester

12:00 p.m. – 12:20 p.m.
Continuous therapy
Michel Attal, Toulouse

12:20 p.m. – 12:40 p.m.
Fixed duration of therapy
Katja Weisel, Tübingen

12:40 p.m. – 12:50 p.m.
Debate All

12:50 p.m. –1:35 p.m. Lunch Buffet

1:35 p.m. – 2:15 p.m. SESSION VI
Gaining insight to the German study groups
Chairmen: Katja Weisel, Tübingen/Heinz Ludwig, Wien

1:35 p.m. – 1:55 p.m.
DSMM – Deutsche Studiengruppe Multiples Myelom
Stefan Knop, Würzburg

1:55 p.m. – 2:15 p.m.
GMMG – German-speaking Myeloma Multicenter Group
Hartmut Goldschmidt, Heidelberg

2:15 p.m. – 3:55 p.m. SESSION VII
Therapy of Multiple Myeloma – Drugs and Treatment Strategies II
Chairmen: Marc-Steffen Raab, Heidelberg/
Michel Attal, Toulouse
2:15 p.m. – 2:35 p.m.  
Significance of allogeneic stem cell transplantation  
Nicolaus Kröger, Hamburg

2:35 p.m. – 2:55 p.m.  
Single vs. double transplantation  
Roman Hajek, Ostrava

2:55 p.m. – 3:15 p.m.  
Immunomodulatory drugs in the treatment of multiple myeloma  
Anders Waage, Trondheim

3:15 p.m. – 3:35 p.m.  
Improvement of therapy of multiple myeloma with new proteasome inhibitors  
Christof Scheid, Köln

3:35 p.m. – 3:55 p.m.  
Monoclonal antibody-based therapies – the newest developments  
Torben Plesner, Vejle

3:55 p.m. – 16:00 p.m. Summary of the 6th Heidelberg Myeloma Workshop  
Hartmut Goldschmidt, Heidelberg

Organisation and Congress venue

5th and 6th May 2017

Congress venue

Pre Conference Scientific Workshop on bone metabolism and bone substitute materials  
(related to SFB Transregio 79)  
National Center for Tumor Diseases  
Room K2/K3  
Im Neuenheimer Feld 460  
69120 Heidelberg

6th Heidelberg Myeloma Workshop  
Medizinische Klinik Heidelberg  
Lecture Hall  
Im Neuenheimer Feld 410  
69120 Heidelberg

Contact and registration

Katja Weisert  
Sektion Multiples Myelom  
Medizinische Klinik V  
Universitätsklinikum Heidelberg

Phone: +49 6221 56-5427  
Fax: +49 6221 56-5647  
E-Mail: katja.weisert@med.uni-heidelberg.de

Or register online at:  
www.myelomaworkshop.de
We would like to thank all our sponsors for supporting the 6th Heidelberg Myeloma Workshop 2017.

AbbVie Deutschland GmbH & Co.KG
65189 Wiesbaden
4,000 Euro

Amgen GmbH
80992 München
50,000 Euro

Bristol-Myers Squibb GmbH & Co. KGaA
80636 München
30,000 Euro

Chugai Pharma Europe Ltd.
60528 Frankfurt am Main
3,000 Euro

Celgene GmbH
81829 München
50,000 Euro

MorphoSys AG
82152 Planegg
5,000 Euro

Sanofi-Aventis Deutschland GmbH
10785 Berlin

The Binding Site GmbH
68723 Schwetzingen
2,000 Euro

Takeda Pharma Vertrieb GmbH & Co. KG
10117 Berlin
50,000 Euro

Sponsors will receive the opportunity to advertise their presentations before and/or after the event.

Educational Grant

Janssen-Cilag GmbH
41470 Neuss
50,000 Euro